Clinical Trial To Test Safety of Stem Cell-Derived Therapy for Type 1 Diabetes

UC San Diego is initial site for first-in-human testing of implanted cell therapy

Researchers at the University of California, San Diego School of Medicine, in partnership with ViaCyte, Inc., a San Diego-based biotechnology firm specializing in regenerative medicine, have launched the first-ever human Phase I/II clinical trial of a stem cell-derived therapy for patients with Type 1 diabetes. … Read the full story from the UCSD Newsroom


Principal investigator in the study is Robert R. Henry, MD, professor of medicine in the Division of Endocrinology and Metabolism at UC San Diego and chief of the Section of Endocrinology, Metabolism & Diabetes at the Veterans Affairs San Diego Healthcare System.

Two Studies Identify Potential New Drug for Crohn’s Disease and Ulcerative Colitis

Vedolizumab, a new intravenous antibody medication, has shown positive results for treating both Crohn’s disease and ulcerative colitis, according to researchers at the University of California San Diego, School of Medicine. The findings, published in two papers, will appear in the August 22 issue of the New England Journal of Medicine (NEJM).Read the full story from the UCSD Newsroom

UC San Diego Health System Video:
 

William Sandborn, MD,William J. Sandborn, MD professor of clinical medicine and chief of the Division of Gastroenterology, was lead investigator in the Crohn’s disease study and co-investigator in the ulcerative colitis study. He is director of UC San Diego Health System’s Inflammatory Bowel Disease Center.

Sandborn joined the University of California, San Diego School of Medicine faculty from the Mayo Clinic in Rochester, Minnesota, in January 2011. There, he was Dorothy A. Adair Professor of Medicine, vice chair of the Mayo Clinic Division of Gastroenterology and Hepatology, and associate dean of research for Intellectual Property and Industry Relations.

Citations for the study reports:

Sandborn WJ, Feagan BG, Rutgeerts P, Hanauer S, Colombel J-F, Sands BE, Lukas M, Fedorak RN, Lee S, Bressler B, Fox I, Rosario M, Sankoh S, Xu J, Stephens K, Milch C and Parikh A for the GEMINI 2 Study Group. Vedolizumab as Induction and Maintenance Therapy for Crohn’s Disease. N Engl J Med 2013; 369:711-721 August 22, 2013DOI: 10.1056/NEJMoa1215739. |  Full text (UCSD only)

Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel J-F, Sandborn WJ, Van Assche G,  Axler J, Kim H-J, Danese S, Fox I, Milch C, Sankoh S, Wyant T, Xu J and Parikh A for the GEMINI 1 Study Group. Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med 2013; 369:699-710 August 22, 2013DOI: 10.1056/NEJMoa1215734. |  Full text (UCSD only)

More Information:

Clinical Trial Evaluates Engineered Smallpox Vaccine as Potential Liver Cancer Killer

As part of a multicenter clinical trial, researchers at University of California, San Diego School of Medicine are evaluating Pexa-Vec (JX-594) to slow the progression of hepatocellular carcinoma (HCC) or liver cancer. Pexa-Vec is a genetically engineered virus that is used in the smallpox vaccine.. … Read the full story from the UCSD Newsroom


Dr. Tony ReidPhysician-scientist Tony Reid, MD, PhD, is principal investigator of this clinical trial of Pexa-Vec (JX-594) at UC San Diego, which is one of 42 sites participating in the study.

Reid is professor of medicine and medical oncologist in the Gastrointestinal Cancer Unit of the UCSD Moores Cancer Center. He conducts research in the center’s Solid Tumor Therapeutics Program.

For more information about the Pexa-Vec (known as TRAVERSE) clinical trial, call 858-822-5354 or visit http://traversetrial.com.

UCSD Health Sciences Partners with Pfizer to Speed Drug Delivery

Research agreement could represent more than $50 million over five years for development of new therapies to benefit major medical needs

In an innovative collaboration designed to speed the process of drug discovery, Pfizer, Inc. and the University of California, San Diego Health Sciences announced today that UC San Diego has joined the ranks of other top-tier life science research institutions across the country as part of Pfizer’s Centers for Therapeutic Innovation (CTI)…. Read the full story from the UCSD Newsroom